{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:35:14Z","timestamp":1787740514595,"version":"build-2784847793"},"reference-count":96,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nutr."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD), previously defined as non-alcoholic fatty liver disease (NAFLD) or metabolic dysfunction-associated fatty liver disease (MAFLD), is the leading cause of chronic liver disease worldwide, with a pathophysiological spectrum ranging from steatosis to steatohepatitis and fibrosis. Lipoprotein(a) [Lp(a)] is an atherogenic lipoprotein, which is associated with increased cardiovascular disease (CVD) risk and has been recently reported as a potential biomarker for MASLD. This systematic review and meta-analysis aimed to present an updated evidence synthesis on the potential link between circulating Lp(a) concentrations and this prevalent hepatic disease in adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed, Embase, CINAHL, and Scopus were searched for eligible studies published in English without a date restriction. Risk of bias (RoB) and study quality were assessed using the Revised RoB Assessment Tool for Nonrandomised Studies (RoBANS 2) and the National Institute of Health quality assessment tool, respectively. Three-level meta-regression performed reporting the pooled mean difference of circulating Lp(a) concentrations between adults with MASLD or NAFLD or MAFLD and controls without these conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Twenty-one observational studies were included in this meta-analysis (137,494 cases; 281,261 controls). A three-level meta-analysis resulted in a pooled mean difference of 1.40\u202fmg\/dL [95% confidence interval: \u22122.81, 5.61;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.50], indicating no significant difference in circulating Lp(a) concentrations between patients with MASLD or NAFLD or MAFLD and controls. Considerable between-study heterogeneity was observed (\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u202f=\u202f95.7%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings provide up-to-date, comprehensive evidence indicating that there are no significant differences in circulating Lp(a) concentrations between adults with metabolic-related steatosis\/steatohepatitis and controls. This suggests limited potential for circulating Lp(a) as a diagnostic\/prognostic biomarker for MASLD, although this biomarker could still be utilized to assess CVD risk in the context of steatotic liver disease. Future prospective studies are required to further explore the clinical utility of circulating Lp(a) as a biomarker in MASLD, particularly for long-term CVD outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD42024607750<\/jats:ext-link>\n                      , Identifier: CRD42024607750.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnut.2026.1778393","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T04:41:39Z","timestamp":1778215299000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Circulating lipoprotein(a) levels and steatotic liver disease related to metabolic dysfunction in adults: an updated systematic review and meta-analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Attia","family":"Mustafa","sequence":"first","affiliation":[{"name":"Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism (WISDEM), University Hospitals Coventry and Warwickshire NHS Trust","place":["Coventry, United Kingdom"]},{"name":"Warwick Medical School, University of Warwick","place":["Coventry, United Kingdom"]},{"name":"Institute for Cardiometabolic Medicine, University Hospitals Coventry and Warwickshire NHS Trust","place":["Coventry, United Kingdom"]},{"name":"Department of Internal Medicine, Faculty of Medicine, Omar Al-Mukhtar University","place":["Al-Bayda, Libya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Dallaway","sequence":"additional","affiliation":[{"name":"Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism (WISDEM), University Hospitals Coventry and Warwickshire NHS Trust","place":["Coventry, United Kingdom"]},{"name":"School of Health and Wellbeing, Faculty of Education, Health and Wellbeing, University of Wolverhampton","place":["Wolverhampton, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukasz","family":"Lagojda","sequence":"additional","affiliation":[{"name":"Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism (WISDEM), University Hospitals Coventry and Warwickshire NHS Trust","place":["Coventry, United Kingdom"]},{"name":"Sheffield Centre for Health and related Research (SCHARR), School of Medicine and Population Health, University of Sheffield","place":["Sheffield, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Kite","sequence":"additional","affiliation":[{"name":"Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism (WISDEM), University Hospitals Coventry and Warwickshire NHS Trust","place":["Coventry, United Kingdom"]},{"name":"School of Health and Wellbeing, Faculty of Education, Health and Wellbeing, University of Wolverhampton","place":["Wolverhampton, United Kingdom"]},{"name":"Division of Public Health, Sport and Wellbeing, Faculty of Health, Medicine and Society, University of Chester","place":["Chester, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah","family":"Abdelhameed","sequence":"additional","affiliation":[{"name":"Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism (WISDEM), University Hospitals Coventry and Warwickshire NHS Trust","place":["Coventry, United Kingdom"]},{"name":"Institute for Cardiometabolic Medicine, University Hospitals Coventry and Warwickshire NHS Trust","place":["Coventry, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamaljit Kaur","family":"Chatha","sequence":"additional","affiliation":[{"name":"Warwick Medical School, University of Warwick","place":["Coventry, United Kingdom"]},{"name":"Institute for Cardiometabolic Medicine, University Hospitals Coventry and Warwickshire NHS Trust","place":["Coventry, United Kingdom"]},{"name":"Department of Biochemistry and Immunology, University Hospitals Coventry and Warwickshire NHS Trust","place":["Coventry, United Kingdom"]},{"name":"Institute of Precision Diagnostics and Translational Medicine, University Hospitals Coventry and Warwickshire NHS Trust","place":["Coventry, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anirudh","family":"Suresh","sequence":"additional","affiliation":[{"name":"Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism (WISDEM), University Hospitals Coventry and Warwickshire NHS Trust","place":["Coventry, United Kingdom"]},{"name":"Warwick Medical School, University of Warwick","place":["Coventry, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harpal S.","family":"Randeva","sequence":"additional","affiliation":[{"name":"Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism (WISDEM), University Hospitals Coventry and Warwickshire NHS Trust","place":["Coventry, United Kingdom"]},{"name":"Warwick Medical School, University of Warwick","place":["Coventry, United Kingdom"]},{"name":"Institute for Cardiometabolic Medicine, University Hospitals Coventry and Warwickshire NHS Trust","place":["Coventry, United Kingdom"]},{"name":"Discoveries in Life Sciences Research Centre, Coventry University","place":["Coventry, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Kyrou","sequence":"additional","affiliation":[{"name":"Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism (WISDEM), University Hospitals Coventry and Warwickshire NHS Trust","place":["Coventry, United Kingdom"]},{"name":"Warwick Medical School, University of Warwick","place":["Coventry, United Kingdom"]},{"name":"Institute for Cardiometabolic Medicine, University Hospitals Coventry and Warwickshire NHS Trust","place":["Coventry, United Kingdom"]},{"name":"Discoveries in Life Sciences Research Centre, Coventry University","place":["Coventry, United Kingdom"]},{"name":"Aston Medical School, College of Health and Life Sciences, Aston University","place":["Birmingham, United Kingdom"]},{"name":"College of Health, Psychology and Social Care, University of Derby","place":["Derby, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s13679-024-00574-z","article-title":"Non-invasive scores and serum biomarkers for fatty liver in the era of metabolic dysfunction-associated steatotic liver disease (MASLD): a comprehensive review from NAFLD to MAFLD and MASLD","volume":"13","author":"Abdelhameed","year":"2024","journal-title":"Curr Obes Rep"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"101215","DOI":"10.1016\/j.diabet.2020.101215","article-title":"NAFLD, and cardiovascular and cardiac diseases: factors influencing risk, prediction and treatment","volume":"47","author":"Targher","year":"2021","journal-title":"Diabetes Metab"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"11275","DOI":"10.3390\/ijms262311275","article-title":"Cardiovascular disease in the context of metabolic dysfunction-associated steatotic liver disease (MASLD): a comprehensive narrative review","volume":"26","author":"Mustafa","year":"2025","journal-title":"Int J Mol Sci"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1161\/CIR.0000000000001303","article-title":"2025 heart disease and stroke statistics: a report of US and global data from the American Heart Association","volume":"151","author":"Martin","year":"2025","journal-title":"Circulation"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"355","DOI":"10.5114\/aoms\/202213","article-title":"2024: the year in cardiovascular disease\u2013the year of lipoprotein (a). Research advances and new findings","volume":"21","author":"Sosnowska","year":"2025","journal-title":"Arch Med Sci"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1699-0463.1963.tb01808.x","article-title":"A new serum type system in man\u2014the Lp system","volume":"59","author":"Berg","year":"1963","journal-title":"Acta Pathol Microbiol Scand"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1172\/JCI113849","article-title":"Changes of genetic apolipoprotein phenotypes caused by liver transplantation. Implications for apolipoprotein synthesis","volume":"83","author":"Kraft","year":"1989","journal-title":"J Clin Invest"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/j.1365-2796.2012.02592.x","article-title":"Lipoprotein (a): resurrected by genetics","volume":"273","author":"Kronenberg","year":"2013","journal-title":"J Intern Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s11789-017-0084-1","article-title":"Lipoprotein (a) and its role in inflammation, atherosclerosis and malignancies","volume":"12","author":"Ors\u00f3","year":"2017","journal-title":"Clin Res Cardiol Suppl"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"583","DOI":"10.5551\/jat.RV17034","article-title":"Lipoprotein (a) as an old and new causal risk factor of atherosclerotic cardiovascular disease","volume":"26","author":"Tada","year":"2019","journal-title":"J Atheroscler Thromb"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.jacc.2022.06.019","article-title":"Ancestry, lipoprotein (a), and cardiovascular risk thresholds: JACC review topic of the week","volume":"80","author":"Tsimikas","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/S0140-6736(18)30134-X","article-title":"Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies","volume":"391","author":"Wood","year":"2018","journal-title":"Lancet"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1161\/CIRCULATIONAHA.107.715698","article-title":"Extreme lipoprotein (a) levels and risk of myocardial infarction in the general population: the Copenhagen City heart study","volume":"117","author":"Kamstrup","year":"2008","journal-title":"Circulation"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein (a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp (a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated lipoprotein (a) and risk of aortic valve stenosis in the general population","volume":"63","author":"Kamstrup","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa1109034","article-title":"Genetic associations with valvular calcification and aortic stenosis","volume":"368","author":"Thanassoulis","year":"2013","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1001\/jamacardio.2022.0987","article-title":"Lipoprotein (a) and its significance in cardiovascular disease: a review","volume":"7","author":"Lau","year":"2022","journal-title":"JAMA Cardiol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.jacc.2023.12.031","article-title":"Lipoprotein (a) and major adverse cardiovascular events in patients with or without baseline atherosclerotic cardiovascular disease","volume":"83","author":"Berman","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"101238","DOI":"10.1016\/j.molmet.2021.101238","article-title":"Metabolic-associated fatty liver disease and lipoprotein metabolism","volume":"50","author":"Heeren","year":"2021","journal-title":"Mol Metabol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/00004836-200308000-00017","article-title":"Serum lipids, lipoproteins and apolipoproteins levels in patients with nonalcoholic steatohepatitis","volume":"37","author":"Koruk","year":"2003","journal-title":"J Clin Gastroenterol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12944-020-01310-x","article-title":"Lipoprotein a, combined with alanine aminotransferase and aspartate aminotransferase, contributes to predicting the occurrence of NASH: a cross-sectional study","volume":"19","author":"Zhang","year":"2020","journal-title":"Lipids Health Dis"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"155294","DOI":"10.1016\/j.metabol.2022.155294","article-title":"Novel metabolic classification for extrahepatic complication of metabolic associated fatty liver disease: a data-driven cluster analysis with international validation","volume":"136","author":"Ye","year":"2022","journal-title":"Metabolism"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"e0253298","DOI":"10.1371\/journal.pone.0253298","article-title":"Significantly higher atherosclerosis risks in patients with obstructive sleep apnea and non-alcoholic fatty liver disease","volume":"16","author":"Sukahri","year":"2021","journal-title":"PLoS One"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"584396","DOI":"10.3389\/fmed.2020.584396","article-title":"Distinct cause of death profiles of hospitalized non-alcoholic fatty liver disease: a 10 years' cross-sectional multicenter study in China","volume":"7","author":"Lin","year":"2021","journal-title":"Front Med"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"e63019","DOI":"10.7759\/cureus.63019","article-title":"Relationship between metabolic dysfunction-associated steatotic liver disease and lipoprotein (a) and other biomarkers","volume":"16","author":"Rossi","year":"2024","journal-title":"Cureus"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1016\/j.dld.2021.02.003","article-title":"Apolipoproteins and liver parameters optimize cardiovascular disease risk-stratification in nonalcoholic fatty liver disease","volume":"53","author":"Wu","year":"2021","journal-title":"Dig Liver Dis"},{"key":"ref32","first-page":"12","article-title":"Serum levels of acute phase proteins in patients with nonalcoholic steatohepatitis","volume":"14","author":"Koruk","year":"2003","journal-title":"Turk J Gastroenterol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"5071","DOI":"10.3402\/ljm.v5i0.5071","article-title":"A preliminary study of inflammatory markers in non-alcoholic steatohepatitis patients","volume":"5","author":"Priya","year":"2010","journal-title":"Libyan J Med"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1111\/jgh.12077","article-title":"Apolipoprotein B\/AI ratio is independently associated with non-alcoholic fatty liver disease in nondiabetic subjects","volume":"28","author":"Choe","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.cca.2016.07.003","article-title":"Association between lipoprotein (a) and nonalcoholic fatty liver disease among Korean adults","volume":"461","author":"Nam","year":"2016","journal-title":"Clin Chim Acta"},{"key":"ref36","first-page":"10","article-title":"Assessment of hepatic steatosis algorithms in non-alcoholic fatty liver disease","volume":"22","author":"Eremi\u0107-Koji\u0107","year":"2018","journal-title":"Hippokratia"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2020.07.020","article-title":"Serum lipoprotein (a) levels and insulin resistance have opposite effects on fatty liver disease","volume":"308","author":"Jung","year":"2020","journal-title":"Atherosclerosis"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"691556","DOI":"10.3389\/fendo.2021.691556","article-title":"Varied relationship of lipid and lipoprotein profiles to liver fat content in phenotypes of metabolic associated fatty liver disease","volume":"12","author":"Wu","year":"2021","journal-title":"Front Endocrinol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"e00504","DOI":"10.14309\/ctg.0000000000000504","article-title":"The ability of lipoprotein (a) level to predict early carotid atherosclerosis is impaired in patients with advanced liver fibrosis related to metabolic associated fatty liver disease","volume":"13","author":"Wu","year":"2022","journal-title":"Clin Transl Gastroenterol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1093\/labmed\/lmad021","article-title":"Associations between apolipoprotein B\/A1 ratio, lipoprotein (a), and the risk of metabolic-associated fatty liver diseases in a Korean population","volume":"54","author":"Park","year":"2023","journal-title":"Lab Med"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21608\/ejchem.2021.104682.4837","article-title":"Novel prognostic indicators to reflect the grade of liver fibrosis in hepatic patients","volume":"65","author":"El-Gazar","year":"2022","journal-title":"Egypt J Chem"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1016\/j.cgh.2024.10.018","article-title":"Lipoprotein (a) in the full Spectrum of metabolic dysfunction-associated Steatotic liver disease: evidence from histologically and genetically characterized cohorts","volume":"23","author":"Fan","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"102613","DOI":"10.1016\/j.dsx.2022.102613","article-title":"Fatty liver and atherogenic dyslipidemia have opposite effects on diabetic micro-and macrovascular disease","volume":"16","author":"Hermans","year":"2022","journal-title":"Diabetes Metab Syndr Clin Res Rev"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1080\/00365520500319591","article-title":"Obesity is the only independent factor associated with ultrasound-diagnosed non-alcoholic fatty liver disease: a cross-sectional case-control study","volume":"41","author":"Lee","year":"2006","journal-title":"Scand J Gastroenterol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"e38340","DOI":"10.1097\/MD.0000000000038340","article-title":"Lipoprotein (a) level predicts the development of nonalcoholic fatty liver disease in Korean adults: a retrospective longitudinal study","volume":"103","author":"Nam","year":"2024","journal-title":"Medicine"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/2046-4053-1-2","article-title":"The nuts and bolts of PROSPERO: an international prospective register of systematic reviews","volume":"1","author":"Booth","year":"2012","journal-title":"Syst Rev"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1471-2288-11-15","article-title":"Methodology in conducting a systematic review of systematic reviews of healthcare interventions","volume":"11","author":"Smith","year":"2011","journal-title":"BMC Med Res Methodol"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/9781119536604.ch3","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"McKenzie","year":"2019"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"249","DOI":"10.4082\/kjfm.23.0034","article-title":"RoBANS 2: a revised risk of bias assessment tool for nonrandomized studies of interventions","volume":"44","author":"Seo","year":"2023","journal-title":"Korean J Fam Med"},{"key":"ref52","volume-title":"Study Quality Assessment Tools 2013","year":"2024"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1161\/CIRCULATIONAHA.113.004406","article-title":"Lipoprotein (a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating Rosuvastatin)","volume":"129","author":"Khera","year":"2014","journal-title":"Circulation"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1177\/0962280216669183","article-title":"Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range","volume":"27","author":"Luo","year":"2018","journal-title":"Stat Methods Med Res"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"ref56","doi-asserted-by":"crossref","DOI":"10.1002\/9781118957813","volume-title":"Meta-Analysis: A Structural Equation Modeling Approach","author":"Cheung","year":"2015"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial. BMJ mental","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Health"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J Stat Softw"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1177\/0013164408315263","article-title":"Dependent correlations in meta-analysis: the case of heterogeneous dependence","volume":"68","author":"Cheung","year":"2008","journal-title":"Educ Psychol Meas"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1002\/sim.1482","article-title":"Improved tests for a random effects meta-regression with a single covariate","volume":"22","author":"Knapp","year":"2003","journal-title":"Stat Med"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/0470870168.ch6","volume-title":"Publication Bias in Meta-Analysis: Prevention, Assessment and Adjustments","author":"Sterne","year":"2005"},{"key":"ref63","volume-title":"metaviz: Forest Plots, Funnel Plots, and Visual Funnel Plot Inference for Meta-Analysis","author":"Kossmeier","year":"2020"},{"key":"ref64","volume-title":"metaviz: Forest Plots, Funnel Plots, and Visual Funnel Plot Inference for Meta-Analysis","author":"Kossmeier","year":"2020"},{"key":"ref65","volume-title":"dmetar: Companion R package for the Guide\u2019 Doing Meta-Analysis in R\u2019. R Package Version 00. 2019;9000","author":"Harrer","year":"2019"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1177\/1745691614553988","article-title":"P-curve and effect size: correcting for publication bias using only significant results","volume":"9","author":"Simonsohn","year":"2014","journal-title":"Perspect Psychol Sci"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1037\/a0033242","article-title":"P-curve: a key to the file-drawer","volume":"143","author":"Simonsohn","year":"2014","journal-title":"J Exp Psychol Gen"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.atherosclerosis.2020.02.026","article-title":"Advanced fibrosis of non-alcoholic steatohepatitis affects the significance of lipoprotein (a) as a cardiovascular risk factor","volume":"299","author":"Konishi","year":"2020","journal-title":"Atherosclerosis"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"947914","DOI":"10.3389\/fendo.2022.947914","article-title":"Glucose metabolism status modifies the relationship between lipoprotein (a) and carotid plaques in individuals with fatty liver disease","volume":"13","author":"Wang","year":"2022","journal-title":"Front Endocrinol"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1002\/hep4.1830","article-title":"Low lipoprotein (a) levels predict hepatic fibrosis in patients with nonalcoholic fatty liver disease","volume":"6","author":"Meroni","year":"2022","journal-title":"Hepatol Communic"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1007\/s12664-023-01457-2","article-title":"Association between hepatic steatosis and lipoprotein (a) levels in non-alcoholic patients: a systematic review","volume":"43","author":"Masson","year":"2024","journal-title":"Indian J Gastroenterol"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"114","DOI":"10.53590\/japt.02.1052","article-title":"The complex role of lipoprotein(a) in the pathophysiology of non-alcoholic fatty liver disease: a systematic review","volume":"14","author":"Kouvari","year":"2023","journal-title":"J Atherosc Prev Treat"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1111\/jgh.16768","article-title":"Circulating lipoprotein (a) in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"39","author":"Nikoli","year":"2024","journal-title":"J Gastroenterol Hepatol"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"576","DOI":"10.3758\/s13428-012-0261-6","article-title":"Three-level meta-analysis of dependent effect sizes","volume":"45","author":"Van den Noortgate","year":"2013","journal-title":"Behav Res Methods"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1037\/a0032968","article-title":"Modeling dependent effect sizes with three-level meta-analyses: a structural equation modeling approach","volume":"19","author":"Cheung","year":"2014","journal-title":"Psychol Methods"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1194\/jlr.R061648","article-title":"Lipoprotein (a) measurements for clinical application","volume":"57","author":"Marcovina","year":"2016","journal-title":"J Lipid Res"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"6018","DOI":"10.3390\/jcm14176018","article-title":"Age-dependent clinical relevance of lipoprotein (a): a comprehensive review from childhood to adulthood","volume":"14","author":"Nasoufidou","year":"2025","journal-title":"J Clin Med"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"475","DOI":"10.5664\/jcsm.3690","article-title":"Effect of obstructive sleep apnea hypopnea syndrome on lipid profile: a meta-regression analysis","volume":"10","author":"Nadeem","year":"2014","journal-title":"J Clin Sleep Med"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/nrn3475","article-title":"Power failure: why small sample size undermines the reliability of neuroscience","volume":"14","author":"Button","year":"2013","journal-title":"Nat Rev Neurosci"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.metabol.2012.07.024","article-title":"Lipoprotein (a) metabolism: potential sites for therapeutic targets","volume":"62","author":"Hoover-Plow","year":"2013","journal-title":"Metabolism"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/0149-2918(95)80048-4","article-title":"Lipoprotein (a) concentration in patients with chronic active hepatitis C before and after interferon treatment","volume":"17","author":"Malaguarnera","year":"1995","journal-title":"Clin Ther"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/0021-9150(94)90006-X","article-title":"Reduced serum lipoprotein (a) levels in patients with primary biliary cirrhosis","volume":"105","author":"Gregory","year":"1994","journal-title":"Atherosclerosis"},{"key":"ref83","first-page":"301","article-title":"Lipoprotein (a) behaviour in patients with hepatocellular carcinoma","volume":"92","author":"Motta","year":"2001","journal-title":"Minerva Med"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.jacl.2023.09.003","article-title":"Discordant association of nonalcoholic fatty liver disease with lipoprotein (a) and markers of atherogenic dyslipidemia","volume":"17","author":"Mehta","year":"2023","journal-title":"J Clin Lipidol"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s10654-021-00778-w","article-title":"Modern epidemiology, 4th edition. TL lash, TJ VanderWeele, S Haneuse, KJ Rothman. Wolters Kluwer, 2021","volume":"36","author":"Ahlbom","year":"2021","journal-title":"Eur J Epidemiol"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.atherosclerosis.2014.01.049","article-title":"Lipoprotein (a): fasting and nonfasting levels, inflammation, and cardiovascular risk","volume":"234","author":"Langsted","year":"2014","journal-title":"Atherosclerosis"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.atherosclerosis.2019.08.015","article-title":"Comparison of lipoprotein (a) serum concentrations measured by six commercially available immunoassays","volume":"289","author":"Scharnagl","year":"2019","journal-title":"Atherosclerosis"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1161\/01.ATV.16.12.1568","article-title":"Lipoprotein (a) in stored plasma samples and the ravages of time: why epidemiological studies might fail","volume":"16","author":"Kronenberg","year":"1996","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.atherosclerosis.2022.04.008","article-title":"Lipoprotein (a) measurement issues: are we making a mountain out of a molehill?","volume":"349","author":"Kronenberg","year":"2022","journal-title":"Atherosclerosis"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1093\/clinchem\/41.2.246","article-title":"Effect of the number of apolipoprotein (a) kringle 4 domains on immunochemical measurements of lipoprotein (a)","volume":"41","author":"Marcovina","year":"1995","journal-title":"Clin Chem"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.atherosclerosis.2022.04.005","article-title":"Lipoprotein (a) and ethnicities","volume":"349","author":"Mehta","year":"2022","journal-title":"Atherosclerosis"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"e70208","DOI":"10.1111\/liv.70208","article-title":"Association of plasma lipoprotein (a) with major adverse cardiovascular events in MASLD with or without advanced liver fibrosis","volume":"45","author":"Xiao","year":"2025","journal-title":"Liver Int"},{"key":"ref93","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4324\/9781315244426-20","volume-title":"Research Ethics","author":"Concato","year":"2017"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1017\/S0266462312000086","article-title":"The effect of English-language restriction on systematic review-based meta-analyses: a systematic review of empirical studies","volume":"28","author":"Morrison","year":"2012","journal-title":"Int J Technol Assess Health Care"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.atherosclerosis.2019.10.011","article-title":"HEART UK consensus statement on lipoprotein (a): a call to action","volume":"291","author":"Cegla","year":"2019","journal-title":"Atherosclerosis"}],"container-title":["Frontiers in Nutrition"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2026.1778393\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T04:41:48Z","timestamp":1778215308000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2026.1778393\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":96,"alternative-id":["10.3389\/fnut.2026.1778393"],"URL":"https:\/\/doi.org\/10.3389\/fnut.2026.1778393","relation":{},"ISSN":["2296-861X"],"issn-type":[{"value":"2296-861X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"article-number":"1778393"}}